p11 Regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells

The defining characteristic of a tumor cell is its ability to escape the constraints imposed by neighboring cells, invade the surrounding tissue, and metastasize to distant sites. This invasive property of tumor cells is dependent on activation of proteases at the cell surface. Most cancer cells secrete the urokinase‐type plasminogen activator, which converts cell‐bound plasminogen to plasmin. Here we address the issue of whether the plasminogen binding protein, p11, plays a significant role in this process. Transfection of human HT1080 fibrosarcoma cells with the human p11 gene in the antisense orientation resulted in a loss of p11 protein from the cell surface and concomitant decreases in cellular plasmin production, ECM degradation, and cellular invasiveness. The transfected cells demonstrated reduced development of lung metastatic foci in SCID mice. In contrast, HT1080 cells transfected with the p11 gene in the sense orientation displayed increased cell surface p11 protein and concomitant increases in cellular plasmin production, as well as enhanced ECM degradation and enhanced cellular invasiveness. The p11 overexpressing cells showed enhanced development of lung metastatic foci. These data establish that changes in the extracellular expression of the plasminogen receptor protein, p11, dramatically affect tumor cell‐mediated pericellular proteolysis.—Choi, K.‐S., Fogg, D. K., Yoon, C. S., Waisman, D. M. p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. FASEB J. 17, 235–246 (2003)

[1]  D. Waisman,et al.  The p11 subunit of annexin II heterotetramer is regulated by basic carboxypeptidase. , 2002, Biochemistry.

[2]  M. Hollenberg,et al.  Activation of p38 and ERK Signaling during Adenovirus Vector Cell Entry Lead to Expression of the C-X-C Chemokine IP-10 , 2002, Journal of Virology.

[3]  M. Ranson,et al.  The topology of plasminogen binding and activation on the surface of human breast cancer cells , 2001, British Journal of Cancer.

[4]  MS Pepper,et al.  Extracellular Proteolysis and Angiogenesis , 2001, Thrombosis and Haemostasis.

[5]  V. Pancholi,et al.  Multifunctional α-enolase: its role in diseases , 2001, Cellular and Molecular Life Sciences CMLS.

[6]  A. Mazar,et al.  The role of the plasminogen activation system in angiogenesis and metastasis. , 2001, Surgical oncology clinics of North America.

[7]  L. Miles,et al.  Purification, Cloning, and Characterization of a Profibrinolytic Plasminogen-binding Protein, TIP49a* , 2001, The Journal of Biological Chemistry.

[8]  Bonnie F. Sloane,et al.  Human Procathepsin B Interacts with the Annexin II Tetramer on the Surface of Tumor Cells* , 2000, The Journal of Biological Chemistry.

[9]  Bonnie F. Sloane,et al.  Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. , 2000, Biochimica et biophysica acta.

[10]  D. Waisman,et al.  Regulation of plasmin activity by annexin II tetramer. , 2000, Biochemistry.

[11]  D. Waisman,et al.  Role of annexin II tetramer in plasminogen activation. , 1999, Trends in cardiovascular medicine.

[12]  S. Mustjoki,et al.  Plasminogen activation in human leukemia and in normal hematopoietic cells , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[13]  D. Waisman,et al.  The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. , 1998, Biochemistry.

[14]  L. Karns,et al.  Characterization of the Binding Sites for Plasminogen and Tissue-Type Plasminogen Activator in Cytokeratin 8 and Cytokeratin 18 , 1998, Journal of protein chemistry.

[15]  J. Félez Plasminogen binding to cell surfaces , 1998 .

[16]  H. Lijnen,et al.  Regulation of Gelatinase Activity in Mice with Targeted Inactivation of Components of the Plasminogen/Plasmin System , 1998, Thrombosis and Haemostasis.

[17]  A. Shinomiya,et al.  The Role of Annexin II Tetramer in the Activation of Plasminogen* , 1998, The Journal of Biological Chemistry.

[18]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[19]  L. Zanetta,et al.  Control of type IV collagenase activity by components of the urokinase–plasmin system: a regulatory mechanism with cell‐bound reactants , 1997, The EMBO journal.

[20]  S. L. Gonias,et al.  Cell-surface Cytokeratin 8 Is the Major Plasminogen Receptor on Breast Cancer Cells and Is Required for the Accelerated Activation of Cell-associated Plasminogen by Tissue-type Plasminogen Activator* , 1996, The Journal of Biological Chemistry.

[21]  V. Ellis Functional Analysis of the Cellular Receptor for Urokinase in Plasminogen Activation , 1996, The Journal of Biological Chemistry.

[22]  M. Scully,et al.  Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase. , 1995, The Biochemical journal.

[23]  E. Plow,et al.  Receptors for plasminogen and t-PA: an update. , 1995, Bailliere's clinical haematology.

[24]  S. L. Gonias,et al.  A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. , 1995, Journal of cell science.

[25]  K. Hajjar,et al.  An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. , 1994, The Journal of biological chemistry.

[26]  K. Hajjar,et al.  An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. , 1994, The Journal of biological chemistry.

[27]  K. Danø,et al.  Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. , 1993, The Journal of biological chemistry.

[28]  W. Laug,et al.  Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells , 1992, International journal of cancer.

[29]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[30]  K. Danø,et al.  Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[31]  Jordi Félez,et al.  Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. , 1991, Biochemistry.

[32]  A. Vaheri,et al.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants , 1989, The Journal of cell biology.

[33]  S. Thorsen,et al.  The course and prerequisites of Lys-plasminogen formation during fibrinolysis. , 1988, Biochemistry.

[34]  J. Plescia,et al.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type , 1986, The Journal of cell biology.

[35]  T. Yeatman,et al.  Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells , 2004, Clinical & Experimental Metastasis.

[36]  D. Waisman,et al.  Role of Annexin II Tetramer in the Regulation of Plasmin Activity , 2003 .

[37]  V. Pancholi,et al.  Multifunctional alpha-enolase: its role in diseases. , 2001, Cellular and molecular life sciences : CMLS.

[38]  Y. DeClerck,et al.  Proteases and protease inhibitors in tumor progression. , 1997, Advances in experimental medicine and biology.

[39]  A. Vaheri,et al.  Plasminogen activation on tumor cell surface and its involvement in human leukemia. , 1996, Advances in cancer research.

[40]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[41]  P. Jones,et al.  Glycoprotein, elastin, and collagen secretion by rat smooth muscle cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.